biotechnology
Biontech and curevac end patent dispute
A few weeks ago it became known that Biontech wanted to take over the German competitor. Now an obstacle has been removed on the way there.
Before the German competitor Biontech’s takeover, the two companies from Tübingen and Mainz have settled their patent dispute around Corona vaccine patent. Among other things, Biontech’s millions of Biontech and its British partner Glaxosmithklin (GSK) were agreed.
The takeover of the Tübinger by Biontech is to be completed as planned by the end of the year. A considerable part of the money paid in the course of the comparison agreement will be back in the Biontech cash register after completing the takeover.
It’s also about a license
According to companies, a total of $ 740 million from Biontech will flow to Curevac and GSK, the amount is divided between Curevac and GSK in half. In addition, Biontech pays a license fee of 1 percent of revenue with COVID 19-vaccine in the USA from January 1, 2025. Curevac in turn transfers GSK $ 50 million.
It was also agreed that Curevac Biontech and its US partner Pfizer grants a non-exclusive license for the production and sale of COVID-19-19 and influenza products on a mRNA-based in the United States. After the Curevac takeover by Biontech, this is expanded into a global license.
Biontech and Curevac had a race for the approval of a Corona vaccine with competitors in pandemic. While Biontech launched his vaccin and made billions in sales, Curevac failed with the plan to launch a vaccine in good time. Curevac later called for participation in the income and saw a violation of a number of his intellectual property rights. Biontech now emphasized that the comparison agreement was not an admission of guilt.
dpa
Source: Stern
